{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:51:20Z","timestamp":1790895080358,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Contracept Reprod Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sickle cell disease (SCD) is a chronic inflammatory condition characterized by hemoglobin polymerization that precipitates recurrent vaso-occlusion, endothelial dysfunction, and multi-organ damage. Menstruation in persons with SCD presents a unique challenge due to blood loss and its ability to exacerbate SCD pain. This interaction between SCD-related vascular stress and menstruation-induced inflammation amplifies the risk of acute pain episodes during menstruation. In this manuscript, we explore the intersection of SCD and menstruation, emphasizing the role of hormonal therapy in managing menstruation-associated acute SCD pain. Progestin-only therapies, such as depot medroxyprogesterone acetate (DMPA) and levonorgestrel intrauterine devices (LNG-IUDs), are particularly effective in reducing menstrual blood loss. Data suggests DMPA mitigates acute SCD pain episodes around menstruation with minimal thrombotic risk in persons with SCD. Despite their effectiveness in menstrual regulation, combined hormonal contraceptives (CHCs) pose a significant concern due to their potential to exacerbate the hypercoagulable state in individuals with SCD. We highlight the importance of comprehensive care and collaboration between gynecologists and hematologists to optimize the management of menstruation-associated SCD pain.<\/jats:p>","DOI":"10.1186\/s40834-025-00361-8","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T04:43:18Z","timestamp":1743741798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Understanding and treating menstruation associated sickle cell pain"],"prefix":"10.1186","volume":"10","author":[{"given":"Halimat","family":"Olaniyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bria","family":"Carrithers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layla","family":"Van Doren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"issue":"1","key":"361_CR1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.2022.10233","volume":"328","author":"PL Kavanagh","year":"2022","unstructured":"Kavanagh PL, Fasipe TA, Wun T. Sickle cell disease: A review. JAMA. 2022;328(1):57\u201368.","journal-title":"JAMA"},{"issue":"9","key":"361_CR2","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.3390\/biomedicines11092413","volume":"11","author":"FI Aboderin","year":"2023","unstructured":"Aboderin FI, Oduola T, Davison GM, Oguntibeju OO. A review of the relationship between the immune response, inflammation, oxidative stress, and the pathogenesis of sickle cell anaemia. Biomedicines. 2023;11(9):2413.","journal-title":"Biomedicines"},{"issue":"1","key":"361_CR3","first-page":"44","volume":"112","author":"K Woods","year":"1997","unstructured":"Woods K, Karrison T, Koshy M, Patel A, Friedmann P, Cassel C. Hospital utilization patterns and costs for adult sickle cell patients in Illinois. Public Health Rep Wash DC 1974. 1997;112(1):44\u201351.","journal-title":"Public Health Rep Wash DC 1974"},{"issue":"6","key":"361_CR4","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1046\/j.1365-2265.2001.01432.x","volume":"55","author":"HO Critchley","year":"2001","unstructured":"Critchley HO, Kelly RW, Brenner RM, Baird DT. The endocrinology of menstruation\u2013a role for the immune system. Clin Endocrinol (Oxf). 2001;55(6):701\u201310.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"361_CR5","first-page":"36","volume":"1","author":"M Day","year":"2020","unstructured":"Day M, Bonnet K, Schlundt DG, DeBaun M, Sharma D. Vaso-Occlusive pain and menstruation in sickle cell disease: A focus group analysis. Womens Health Rep New Rochelle N. 2020;1(1):36\u201346.","journal-title":"Womens Health Rep New Rochelle N"},{"issue":"3","key":"361_CR6","doi-asserted-by":"crossref","first-page":"174","DOI":"10.14423\/SMJ.0000000000000949","volume":"112","author":"ME Day","year":"2019","unstructured":"Day ME, Stimpson SJ, Rodeghier M, Ghafuri D, Callaghan M, Zaidi AU, et al. Contraceptive methods and the impact of menstruation on daily functioning in women with sickle cell disease. South Med J. 2019;112(3):174\u20139.","journal-title":"South Med J"},{"issue":"5","key":"361_CR7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0010-7824(97)00156-X","volume":"56","author":"M de Abood","year":"1997","unstructured":"de Abood M, de Castillo Z, Guerrero F, Espino M, Austin KL. Effect of Depo-Provera or microgynon on the painful crises of sickle cell anemia patients. Contraception. 1997;56(5):313\u20136.","journal-title":"Contraception"},{"issue":"2","key":"361_CR8","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1089\/jwh.2018.7147","volume":"28","author":"D Sharma","year":"2019","unstructured":"Sharma D, Day ME, Stimpson SJ, Rodeghier M, Ghafuri D, Callaghan M, et al. Acute Vaso-Occlusive pain is temporally associated with the onset of menstruation in women with sickle cell disease. J Womens Health 2002. 2019;28(2):162\u20139.","journal-title":"J Womens Health 2002"},{"issue":"12","key":"361_CR9","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1089\/jwh.2023.0023","volume":"32","author":"C Segbefia","year":"2023","unstructured":"Segbefia C, Campbell J, Tartaglione I, Asare EV, Andemariam B, Zempsky W, et al. Pain frequency and health care utilization patterns in women with sickle cell disease experiencing Menstruation-Associated pain crises. J Womens Health 2002. 2023;32(12):1284\u201391.","journal-title":"J Womens Health 2002"},{"issue":"4","key":"361_CR10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/01443610220141362","volume":"22","author":"WC Yoong","year":"2002","unstructured":"Yoong WC, Tuck SM. Menstrual pattern in women with sickle cell anaemia and its association with sickling crises. J Obstet Gynaecol J Inst Obstet Gynaecol. 2002;22(4):399\u2013401.","journal-title":"J Obstet Gynaecol J Inst Obstet Gynaecol"},{"issue":"3","key":"361_CR11","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/AOG.0000000000004899","volume":"140","author":"American College of Obstetricians and Gynecologists\u2019 Committee on Clinical Consensus","year":"2022","unstructured":"American College of Obstetricians and Gynecologists\u2019 Committee on Clinical Consensus\u2013Gynecology. General approaches to medical management of menstrual suppression: ACOG clinical consensus 3. Obstet Gynecol. 2022;140(3):528\u201341.","journal-title":"Obstet Gynecol"},{"key":"361_CR12","doi-asserted-by":"crossref","unstructured":"Pecker LH, Hussain S, Lanzkron S, Tao X, Thaler K, Burke AE et al. Women with sickle cell disease report low knowledge and use of long acting reversible contraception. J Natl Med Assoc. 2021;113(5).","DOI":"10.1016\/j.jnma.2021.05.005"},{"key":"361_CR13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.contraception.2021.08.009","volume":"105","author":"AH Roe","year":"2022","unstructured":"Roe AH, Lang B, McAllister A, Gaitors MC, Smith-Whitley K, Schreiber CA, et al. Contraceptive use and preferences among females with sickle cell disease. Contraception. 2022;105:42\u20135.","journal-title":"Contraception"},{"issue":"10","key":"361_CR14","doi-asserted-by":"crossref","first-page":"e29877","DOI":"10.1002\/pbc.29877","volume":"69","author":"MA Askew","year":"2022","unstructured":"Askew MA, Smaldone AM, Gold MA, Smith-Whitley K, Strouse JJ, Jin Z, et al. Pediatric hematology providers\u2019 contraceptive practices for female adolescents and young adults with sickle cell disease: A National survey. Pediatr Blood Cancer. 2022;69(10):e29877.","journal-title":"Pediatr Blood Cancer"},{"key":"361_CR15","doi-asserted-by":"crossref","unstructured":"Carrithers B. Addressing Reproductive Education Among Young Adults with Sickle Cell Disease (SCD): Sickle Cell Reproductive Outreach and Education (ROE) Project. In ASH; 2023 [cited 2024 Nov 3]. Available from: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper190927.html","DOI":"10.1182\/blood-2023-190927"},{"issue":"6","key":"361_CR16","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jadohealth.2021.06.008","volume":"69","author":"M Leroy-Melamed","year":"2021","unstructured":"Leroy-Melamed M, Jacob S, Shew ML, Kazmerski TM. Provider attitudes, preferences, and practices regarding sexual and reproductive health for adolescents and young adults with sickle cell disease. J Adolesc Health. 2021;69(6):970\u20135.","journal-title":"J Adolesc Health"},{"issue":"2","key":"361_CR17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.contraception.2005.08.010","volume":"73","author":"JK Legardy","year":"2006","unstructured":"Legardy JK, Curtis KM. Progestogen-only contraceptive use among women with sickle cell anemia: a systematic review. Contraception. 2006;73(2):195\u2013204.","journal-title":"Contraception"},{"issue":"6","key":"361_CR18","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.contraception.2011.10.008","volume":"85","author":"LB Haddad","year":"2012","unstructured":"Haddad LB, Curtis KM, Legardy-Williams JK, Cwiak C, Jamieson DJ. Contraception for individuals with sickle cell disease: a systematic review of the literature. Contraception. 2012;85(6):527\u201337.","journal-title":"Contraception"},{"issue":"2","key":"361_CR19","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.contraception.2016.10.005","volume":"95","author":"NK Tepper","year":"2017","unstructured":"Tepper NK, Dragoman MV, Gaffield ME, Curtis KM. Nonoral combined hormonal contraceptives and thromboembolism: a systematic review. Contraception. 2017;95(2):130\u20139.","journal-title":"Contraception"},{"issue":"6","key":"361_CR20","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.amjms.2021.07.002","volume":"363","author":"\u00d6 Eskiocak","year":"2022","unstructured":"Eskiocak \u00d6, Y\u0131lmaz M\u00d6, \u0130lhan G. Metabolic bone diseases in sickle cell anemia patients and evaluation of associated factors. Am J Med Sci. 2022;363(6):490\u20134.","journal-title":"Am J Med Sci"},{"key":"361_CR21","doi-asserted-by":"crossref","unstructured":"Nascimento MDLP, Ladipo OA, Coutinho EM. Nomegestrol acetate contraceptive implant use by women with sickle cell disease. Clin Pharmacol Ther. 1998;64(4).","DOI":"10.1016\/S0009-9236(98)90074-1"},{"issue":"1","key":"361_CR22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0020-7292(93)90159-T","volume":"41","author":"OA Ladipo","year":"1993","unstructured":"Ladipo OA, Falusi AG, Feldblum PJ, Osotimehin BO, Otolorin EO, Ojengbede OA. Norplant use by women with sickle cell disease. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 1993;41(1):85\u20137.","journal-title":"Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet"},{"issue":"3","key":"361_CR23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00404-016-4261-0","volume":"295","author":"M Patseadou","year":"2017","unstructured":"Patseadou M, Michala L. Usage of the levonorgestrel-releasing intrauterine system (LNG-IUS) in adolescence: what is the evidence so far? Arch Gynecol Obstet. 2017;295(3):529\u201341.","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"361_CR24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jpag.2021.11.002","volume":"35","author":"PS Huguelet","year":"2022","unstructured":"Huguelet PS, Laurin JL, Thornhill D, Moyer G. Use of the levonorgestrel intrauterine system to treat heavy menstrual bleeding in adolescents and young adults with inherited bleeding disorders and Ehlers-Danlos syndrome. J Pediatr Adolesc Gynecol. 2022;35(2):147\u2013e1521.","journal-title":"J Pediatr Adolesc Gynecol"},{"issue":"5","key":"361_CR25","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.contraception.2008.11.012","volume":"79","author":"D Hubacher","year":"2009","unstructured":"Hubacher D, Chen PL, Park S. Side effects from the copper IUD: do they decrease over time? Contraception. 2009;79(5):356\u201362.","journal-title":"Contraception"},{"issue":"6","key":"361_CR26","doi-asserted-by":"crossref","first-page":"e12763","DOI":"10.1002\/rth2.12763","volume":"6","author":"C LaVasseur","year":"2022","unstructured":"LaVasseur C, Neukam S, Kartika T, Samuelson Bannow B, Shatzel J, DeLoughery TG. Hormonal therapies and venous thrombosis: considerations for prevention and management. Res Pract Thromb Haemost. 2022;6(6):e12763.","journal-title":"Res Pract Thromb Haemost"},{"key":"361_CR27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.thromres.2020.05.008","volume":"192","author":"MY Abou-Ismail","year":"2020","unstructured":"Abou-Ismail MY, Citla Sridhar D, Nayak L. Estrogen and thrombosis: A bench to bedside review. Thromb Res. 2020;192:40\u201351.","journal-title":"Thromb Res"},{"issue":"2","key":"361_CR28","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/bjh.14655","volume":"178","author":"A Brunson","year":"2017","unstructured":"Brunson A, Lei A, Rosenberg AS, White RH, Keegan T, Wun T. Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality. Br J Haematol. 2017;178(2):319\u201326.","journal-title":"Br J Haematol"},{"issue":"9","key":"361_CR29","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1182\/bloodadvances.2019001384","volume":"4","author":"A Srisuwananukorn","year":"2020","unstructured":"Srisuwananukorn A, Raslan R, Zhang X, Shah BN, Han J, Gowhari M, et al. Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease. Blood Adv. 2020;4(9):1978\u201386.","journal-title":"Blood Adv"},{"issue":"8","key":"361_CR30","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1182\/bloodadvances.2019001142","volume":"4","author":"MR DeBaun","year":"2020","unstructured":"DeBaun MR, Jordan LC, King AA, Schatz J, Vichinsky E, Fox CK, et al. American society of hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv. 2020;4(8):1554\u201388.","journal-title":"Blood Adv"},{"key":"361_CR31","doi-asserted-by":"crossref","unstructured":"Nguyen AT, U.S. Medical Eligibility Criteria for Contraceptive Use., 2024. MMWR Recomm Rep [Internet]. 2024 [cited 2024 Nov 3];73. Available from: https:\/\/www.cdc.gov\/mmwr\/volumes\/73\/rr\/rr7304a1.htm","DOI":"10.15585\/mmwr.rr7304a1"},{"issue":"4","key":"361_CR32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.blre.2015.12.003","volume":"30","author":"D Noubouossie","year":"2016","unstructured":"Noubouossie D, Key NS, Ataga KI. Coagulation abnormalities of sickle cell disease: relationship with clinical outcomes and the effect of disease modifying therapies. Blood Rev. 2016;30(4):245\u201356.","journal-title":"Blood Rev"},{"key":"361_CR33","doi-asserted-by":"crossref","unstructured":"Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB et al. U.S. Medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(3).","DOI":"10.15585\/mmwr.rr6503a1"},{"issue":"8292","key":"361_CR34","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(82)90320-8","volume":"2","author":"K De Ceulaer","year":"1982","unstructured":"De Ceulaer K, Gruber C, Hayes R, Serjeant GR. Medroxyprogesterone acetate and homozygous sickle-cell disease. Lancet Lond Engl. 1982;2(8292):229\u201331.","journal-title":"Lancet Lond Engl"},{"issue":"6894","key":"361_CR35","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1136\/bmj.306.6894.1735","volume":"306","author":"RJ Howard","year":"1993","unstructured":"Howard RJ, Lillis C, Tuck SM. Contraceptives, counselling, and pregnancy in women with sickle cell disease. BMJ. 1993;306(6894):1735\u20137.","journal-title":"BMJ"}],"container-title":["Contraception and Reproductive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40834-025-00361-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40834-025-00361-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40834-025-00361-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T04:44:19Z","timestamp":1743741859000},"score":1,"resource":{"primary":{"URL":"https:\/\/contraceptionmedicine.biomedcentral.com\/articles\/10.1186\/s40834-025-00361-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["361"],"URL":"https:\/\/doi.org\/10.1186\/s40834-025-00361-8","relation":{},"ISSN":["2055-7426"],"issn-type":[{"value":"2055-7426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}